Objective: Gastric cancer is the fourth most common malignancy,and the second most common cause of cancermortality worldwide. The aim of this study was to investigatethe role of biomarkers CYFRA 21-1, CA 19-9, CEA,CA72.4 at diagnosis and throughout the follow-up in patientswith gastric cancer.Methods: 30 patients with gastric cancer diagnosed and31 healthy people as a control group were included in thisstudy. According to the TNM staging system, there were16 patients with stage II and 14 patients with stage III inthe group of patients with gastric cancer. CEA, CA 19-9,CA 72-4 and CYFRA 21-1 levels were studied by elektrochemiluminescenceimmunasay (ECLIA) method in theCobas e 601 instrument.Results: Statistically the level of CA 72-4, CA 19-9, CEAand CYFRA 21-1 gastric cancer groups was found significanthigh accaording to healthy control group (p<0.01).Statistically compared with II stage patient group, the levelof CA 19-9, CEA and CYFRA 21-1 of III stage patientgroup was found significant high (p<0.01). The diagnosticcut-off, sensitivity and specificity for CEA were 4.15 ng/mL, 46 % and 96%, respectively; for CA 19-9 were 24.50U/mL, 17 % and 96 %; for CA 72-4 were 2.46 U/mL, 53% and 96% and for CYFRA 21-1 were 3.36 ng/mL, 46%and 100%.Conclusion: Our study demonstrates that the associationof biomarkers CYFRA 21-1, CEA, and CA72.4 providesa valuable contribution in the follow-up of gastriccancer patients.Key words: Gastric cancer, tumor markers, CYFRA 21-